Prot #CYTB323L12201: A Phase 2, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants with Severe Refractory Idiopathic Inflammatory Myopathies

Project: Research project

Project Details

StatusActive
Effective start/end date7/1/24 → 8/1/32

Funding

  • Novartis Pharmaceuticals Corporation (Prot #CYTB323L12201)